“Yes,” he said. “Unfortunately. If I had known what would happen, I would never have done the work.”
I was surprised at his vehemence but not at his sentiment. Even as Hybritech’s sales have risen, the medical establishment has been torn by a debate over whether the concomitant increase in early cancer detection and treatment is a good thing. The PSA test cannot distinguish between a prostate carcinoma that will never disturb its host and one that is ready to invade bone. The fear is that in the next few years tens of thousands of men will undergo needless operations, with an attendant rise in surgically induced impotence, incontinence, and death. For every surgeon who is full of enthusiasm, another medical professional paints the scary picture of a nation full of otherwise healthy retirees in diapers. Indeed, some critics argue that the dispute over prostate cancer is a case study in one of the American medical system's worst shortcomings - its propensity to embrace expensive treatments without considering their longterm social or medical impact.
Just ahead, these critics believe, are tests for Alzheimer's disease and several other types of cancer. All are common conditions with uncertain prospects for cure. Are we to follow the PSA pattern, and sentence the unfortunates who receive bad news to a round of medical intervention that may only increase their misery? Or, as proponents of the PSA test argue, can earlier, better diagnoses be only beneficial?
And what if - as may be the case with prostate cancer -- the benefits of quicker diagnosis and treatment are concentrated among relatively few people, whereas the costs, perhaps much larger, are spread over many more?
Yang is one of these critics. "It's gone out of control," he says. "People don't know what they're doing, and it's going to be a terrible mess. I feel sick about it. It's a disaster for the healthcare system - a horrible disaster. We've rushed ahead and created a nightmare."
The Troublesome Gland
At the center of the dispute is the prostate, a small gland that is frequently burdened in description with adjectives like "obscure," "inessential," and "dumb." Prostates vary considerably in size from man to man, but typical examples are said to be about the size of a walnut and to weigh almost an ounce. They are solid, as opposed to spongy, and are loosely attached to the bottom of the bladder. Their job is to concoct a chemical stew - PSA is one of the ingredients - and add it to semen just before ejaculation. Nobody understands what, precisely, the added compounds do, but they are thought to be important in reproduction.
From an evolutionary point of view, there is little reason for the prostate to keep functioning after the typical age of reproduction - and it doesn't. Indeed, the number of men who escape prostate trouble of any sort is small enough to put the likelihood of experiencing it just below that of death and taxes. No one knows why, though every researcher I have asked has a laundry list of speculations. "Perhaps it is exposed to carcinogens," says Donna Peehl, a specialist in prostate genetics at the Stanford University School of Medicine. "Perhaps the problem is its proximity to the urethra the channel carrying urine from the bladder], with all that urine leaking through. That explanation doesn't work particularly well, though. Perhaps it's a developmental thing, something about the biology of the prostate that is important to its normal behavior but that we don't know yet." Nobody knows, she says. "It's kind of an obscure little gland and yet it causes all this trouble."
The trouble comes in three varieties: prostatitis; benign prostatic hyperplasia (BPH); and prostatic carcinomaprostate cancer. All are diseases of old age, or at least middle age. Prostatitis is simply an infection or inflammation of the prostate. It is extremely common. Indeed, many men have chronic cases that they don't know about and don't need to know about, because the disease poses no longterm threat and in those men has no noticeable effects. In bad cases symptoms occur during urination: a sensation of burning, a need to urinate more often or more urgently than usual, or an inability to release more than a small amount of urine. The standard treatment is antibiotics of a class known as fluoroquinolones; the most common is ciprofloxacin (made by Miles, and sold as Cipro). A successful outcome is taken for granted.
Benign prostatic hyperplasia occurs when the inner portion of the prostate enlarges. The urethra tunnels through the middle of the prostate like a string through a bead. When the prostate swells, it becomes, in effect, a choke collar for the urethra, obstructing the flow of urine. Actually, it becomes a second collar; a band of muscle, the urethral sphincter, already rings one end of the prostate, preventing unwanted urination. That sphincter is under voluntary control; the BPHcaused sphincter is not. Symptoms of BPH include both trouble with urination and, paradoxically, its opposite, trouble with holding back urination, especially at night. By age sixtyfive about three quarters of all men will experience BPH - indeed, that is when some men first learn they own a prostate. The cause of BPH is unknown. It just seems to happen, along with wrinkles, hair on the shoulders and in the ears, and the other irritants of male aging.
BPH is "benign" only as doctors understand the word, which is to say that it is not malignant. ("Hyperplasia" is the unwanted growth of tissue.) It is almost always a bother and sometimes more than that, leading to infections of the urinary tract. If the symptoms are unpleasant enough, doctors recommend treatment. Until recently the most common treatment was transurethral resection of the prostate, or TURP. The surgeon threads a fiberoptic tube through the penis to the prostate, guided by a light at the tip of the tube. Bits of tissue bulge into a hole in the side of the tube, where they are snipped off by a tiny blade and sucked away. Repeated clippings eventually free up the passage. Descriptions of the procedure often include references to "RotoRootering." According to Patrick Walsh, the chairman of the urology department at the Johns Hopkins University School of Medicine, TURP is usually effective, although like all surgery, it is expensivethe full tab often runs to more than $5,000. Longterm difficulties with urinary control continue for about one out of every hundred patients, and fewer than one out of twenty, Walsh says, have subsequent problems with impotence.